Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 17/20 | 0.55 |
| ▸ | EGLN1 | Q9GZT9 | 16/20 | 0.55 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.47 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5141932 | 1.00 | EGLN2 (0.55) | EGLN2EGLN1BBOX1FTO | |
| SCHEMBL30402374 | 0.89 | EGLN2 (0.68) | EGLN2EGLN1 | |
| SCHEMBL964665 | 0.89 | EGLN2 (0.68) | EGLN2EGLN1 | |
| SCHEMBL522778 | 0.89 | EGLN2 (0.68) | EGLN2EGLN1 | |
| SCHEMBL522777 | 0.89 | EGLN2 (0.68) | EGLN2EGLN1 | |
| SCHEMBL523001 | 0.88 | EGLN2 (0.70) | EGLN2EGLN1 | |
| SCHEMBL523000 | 0.88 | EGLN2 (0.70) | EGLN2EGLN1 | |
| SCHEMBL523441 | 0.85 | EGLN2 (0.58) | EGLN2EGLN1 | |
| SCHEMBL523442 | 0.85 | EGLN2 (0.58) | EGLN2EGLN1 | |
| SCHEMBL523565 | 0.83 | EGLN2 (0.58) | EGLN2EGLN1BBOX1FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293575-A1 | Compounds and methods for treatment of cancer-related anemia | FIBROGEN, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293575-A1 | Compounds and methods for treatment of cancer-related anemia | EPOR, THPO, TFRC | EGLN2 11/4885EGLN1 21/4885BBOX1 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.